65
Tanvex BioPharma, Inc.
6541.TW · TAI
$31.90 +2.08% (+$0.65)
1M -16.69%
Market Cap $8.27B
P/E Ratio -
Div. Yield -
ROE 26.72%
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/B 1.54x
P/S 12.57x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 59.95%
Rev. growth 161.57%
FCF growth N/A
Profitability
0 /100
Weak Net margin 222.84%
Op. margin 217.02%
FCF margin 283.07%
Quality
1 /100
Poor ROE 26.72%
ROA 19.18%
Asset turnover 0.09x
Debt
60 /100
Moderate Current ratio 1.33x
Int. coverage -40.76x
Debt/Equity 0.31x
Stability
18 /100
Unstable Rev. volatility 582.40%
EPS volatility 35.21%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre 6541.TW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen Lam
Employees
215
Headquarters
George Town
Evenimente viitoare
16 NOV.
Earnings
Upcoming earnings report